应用抗血管药物联合化疗治疗复发性卵巢癌的Meta分析

发布时间：2018-07-11 21:54

本文选题：抗血管药物 + 复发性卵巢癌　；参考：《广西医科大学》2017年硕士论文

【摘要】：目的评估抗血管药物联合化疗治疗复发性卵巢癌的疗效和安全性。方法通过检索PubMed,EMBASE和the Cochrane Central Register of Controlled Trials数据库中关于抗血管药物治疗复发性卵巢癌的随机对照试验(Randomized controlled trials,RCTs)。根据Cochrane系统评价方法对文献进行筛选、数据提取,并对纳入的文献进行风险偏倚评估,应用RevMan 5.2进行数据统计学分析。结果纳入8项RCT试验,包括3211例复发性卵巢癌患者。每项RCT试验包括实验组和对照组,实验组治疗为抗血管药物联合化疗,对照组为单纯化疗。根据不同抗血管药物类型,将8项RCT研究分成3个组:血管内皮生长因子抑制剂(贝伐单抗)组,血管内皮因子受体抑制剂(VEGFRIs)组和血管生成素抑制剂(trebananib)组。Meta分析结果表明应用三类抗血管药物联合化疗,与其对应的单纯化疗组相比,它们的无进展生存期(PFS)和总体生存期(OS)均明显改善。对于常见的不良事件,VEGFRIs组表现为疲乏,腹泻和高血压;贝伐单抗组为高血压,蛋白尿,胃肠穿孔和动脉血栓栓塞;而trebananib组为低血钾症。结论与单纯化疗相比,应用抗血管药物联合化疗明显延长了PFS和OS;同时抗血管药物联合化疗增加了不良反应的发生率。
[Abstract]:Objective to evaluate the efficacy and safety of anti-vascular drugs combined with chemotherapy in the treatment of recurrent ovarian cancer. Methods by searching the database of the Cochrane Central Register of controlled trials, we searched the randomized controlled trialsof RCTs for recurrent ovarian cancer treated with antivasodilants in the PubMeden EMBASE and the Cochrane Central Register of controlled trials database. According to the Cochrane systematic evaluation method, the literature was screened, the data was extracted, and the risk bias of the included literature was evaluated. Revman 5.2 was used for statistical analysis of the data. Results eight RCT tests were included, including 3211 patients with recurrent ovarian cancer. Each RCT test consisted of experimental group and control group. The experimental group was treated with antivascular drugs combined with chemotherapy, and the control group was treated with chemotherapy alone. According to different types of antivascular drugs, eight RCT studies were divided into three groups: vascular endothelial growth factor inhibitor (Bevatumab) group. Vascular endothelial factor receptor inhibitor (VEGFRIs) group and angiopoietin inhibitor (trebananib) group. Meta-analysis results showed that three kinds of antivascular drugs were used in combination chemotherapy, compared with the corresponding chemotherapy group. Their progressive survival (PFS) and total survival (OS) were significantly improved. The common adverse events were fatigue, diarrhea and hypertension in the VEGFRIs group, hypertension, proteinuria, gastrointestinal perforation and arterial thromboembolism in the bevacizumab group, and hypokalemia in the trebananib group. Conclusion compared with chemotherapy alone, combination chemotherapy with antivascular drugs significantly prolonged PFS and OS.The incidence of adverse reactions was increased by combined chemotherapy with antivascular drugs.
【学位授予单位】：广西医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.31

【相似文献】